Faculty Opinions recommendation of Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK).
2011 ◽
Vol 54
(18)
◽
pp. 6342-6363
◽
2018 ◽
Vol 61
(14)
◽
pp. 1036-1042
2012 ◽
Vol 55
(18)
◽
pp. 8091-8109
◽
2018 ◽
Vol 06
(01)
◽